A5103171712- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- PARP inhibition in cancer therapy
- Immunotherapy and Immune Responses
- Synthesis and Biological Evaluation
- Immune Cell Function and Interaction
- HER2/EGFR in Cancer Research
- DNA Repair Mechanisms
- Protein Degradation and Inhibitors
- Cancer therapeutics and mechanisms
- Neuroblastoma Research and Treatments
- Computational Drug Discovery Methods
- Lung Cancer Treatments and Mutations
- Advanced biosensing and bioanalysis techniques
- Phagocytosis and Immune Regulation
- Microtubule and mitosis dynamics
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- Cell death mechanisms and regulation
AbbVie (United States)
2014-2024
Abbott (United States)
2012
Abstract PARP inhibitors have recently been approved as monotherapies for the treatment of recurrent ovarian cancer and metastatic BRCA-associated breast cancer, ongoing studies are exploring additional indications combinations with other agents. trap onto damaged chromatin when combined temozolomide methyl methanesulfonate, but clinical relevance these findings remains unknown. trapping has thus far undetectable in cells treated alone. Here, we evaluate contribution to tolerability efficacy...
Abstract The antiapoptotic protein BCL2 plays critical roles in regulating lymphocyte development and immune responses, has also been implicated tumorigenesis tumor survival. However, it is unknown whether for antitumor responses. We evaluated venetoclax, a selective small-molecule inhibitor of BCL2, would influence the activity checkpoint inhibitors (ICI). demonstrate mouse syngeneic models that venetoclax can augment efficacy ICIs accompanied by increase PD-1+ T effector memory cells....
Abstract Glucocorticoids are key components of the standard-of-care treatment regimens for B-cell malignancy. However, systemic glucocorticoid is associated with several adverse events. ABBV-319 a CD19-targeting antibody-drug conjugate engineered to reduce glucocorticoid-associated toxicities while possessing 3 distinct mechanisms action (MOA) increase therapeutic efficacy: (1) antibody-mediated delivery receptor modulator (GRM) payload activate apoptosis, (2) inhibition CD19 signaling, and...
CD3 bispecific T-cell engagers (TCE), comprised of a tumor-targeting domain linked to binding domain, function by bridging target-positive tumors and CD3-expressing effector T cells enabling redirected cell-mediated killing tumor cells. Although the majority molecules in clinical development incorporate antibody-based domains, many tumor-associated antigens derive from intracellular proteins are not accessible targeting via antibody. Intracellular processed into short peptide fragments...
// Lindsay R. Stolzenburg 1 , * Barrett Ainsworth Bridget Riley-Gillis Tibor Pakozdi Areej Ammar Paul A. Ellis Julie L. Wilsbacher and Cyril Y. Ramathal AbbVie Inc., North Chicago, IL 60064, USA These authors contributed equally to this work Correspondence to: Ramathal, email: cyril.ramathal@abbvie.com Keywords: PARP inhibitor; veliparib; cisplatin; transcriptomics; NSCLC Abbreviations: PARP: poly(ADP)-ribose polymerase; PARPi: polymerase inhibitors; NSCLC: non-small cell lung cancer; DEGs:...
Abstract Natural killer (NK) cell redirecting therapies are emerging as promising “off the shelf” treatments for cancer without safety issues associated with T directed therapies. ABBV-303 is a novel c-Met targeted multispecific NK engager based on Dragonfly Therapeutics’ TriNKET® technology. includes three functional arms: (1) binding scFv ABT-700, common to c-Met-targeting antibody-drug conjugates ABBV-400 and Teliso-V; (2) Fab arm that binds NKG2D, stimulatory receptor expressed by cells...
<div>Abstract<p>CD3 bispecific T cell engagers (TCE), comprised of a tumor targeting domain linked to CD3 binding domain, function by bridging target-positive tumors and CD3-expressing effector cells enabling redirected cell-mediated killing cells. Although the majority molecules in clinical development incorporate tumor-targeting antibody-based domains, many tumor-associated antigens derive from intracellular proteins are not accessible via antibody. Intracellular processed into...
<p>A prostate tumor cell line (PC3M-A2/beta 2M) was inoculated subcutaneously in the right flank of CD34-humanized NSG mice. Mice were treated intravenously at indicated time points with either vehicle or an ABBV-184 precursor molecule, and size monitored. Tumors experienced transient regression growth inhibition prior to harvest for analysis tumor-infiltrating immune cells.</p>
<p>A prostate tumor cell line (PC3M-A2/beta 2M) was inoculated subcutaneously in the right flank of CD34-humanized NSG mice. Mice were treated intravenously at indicated time points with either vehicle or an ABBV-184 precursor molecule, and size monitored. Tumors experienced transient regression growth inhibition prior to harvest for analysis tumor-infiltrating immune cells.</p>
Abstract PARP-1 and PARP-2 are required for base excision repair (BER) also function to regulate homologous recombination non-homologous end joining. Inhibitors of these enzymes have demonstrated context-dependent anti-tumor activity, particularly in combination with DNA damaging agents tumors deficits. For this reason, there is considerable interest the ongoing clinical development PARP inhibitors as anti-cancer therapies. However, due diversity complexity repair, mechanisms action not been...
Abstract The Aurora kinases are a family of serine/threonine that mediate essential functions in cell division. A depletion results accumulation cells the G2/M phase and apoptosis. Inhibition B/C abnormal division, polyploidy, resulting apoptosis, therefore, present an attractive target for chemotherapy. Cells treated with aurora inhibitors enter mitosis normal kinetics but fail to undergo cytokinesis due mitotic spindle checkpoint disruption. ABT-348 is novel adenosine triphosphate...
Supplementary Data from ABT-888 Confers Broad <i>In vivo</i> Activity in Combination with Temozolomide Diverse Tumors
<div>Abstract<p><b>Purpose:</b> ABT-888, currently in phase 2 trials, is a potent oral poly(ADP-ribose) polymerase inhibitor that enhances the activity of multiple DNA-damaging agents, including temozolomide (TMZ). We investigated ABT-888+TMZ combination therapy xenograft models representing various human tumors having different responses to TMZ.</p><p><b>Experimental Design:</b> efficacy implanted subcutaneous, orthotopic, and metastatic sites...
<div>Abstract<p><b>Purpose:</b> ABT-888, currently in phase 2 trials, is a potent oral poly(ADP-ribose) polymerase inhibitor that enhances the activity of multiple DNA-damaging agents, including temozolomide (TMZ). We investigated ABT-888+TMZ combination therapy xenograft models representing various human tumors having different responses to TMZ.</p><p><b>Experimental Design:</b> efficacy implanted subcutaneous, orthotopic, and metastatic sites...
<p>Supplementary Table 1</p>
<p>Supplementary Figures S1-S10</p>
<p>Supplementary Figures S1-S10</p>
<p>Supplementary Table 1</p>
Abstract Introduction: Glucocorticoids are key components of standard-of-care treatment regimens (e.g., R-CHOP, Hyper-CVAD) for several B-cell malignancies. However, prolonged systemic glucocorticoid results in glucocorticoid-associated adverse events and acquired resistance that limit its therapeutic potential. ABBV-319 is a novel CD19-targeting ADC engineered to reduce toxicity observed with glucocorticoids while possessing three distinct mechanisms action (MoA) increase efficacy: 1)...
<div>Abstract<p>CD3 bispecific T cell engagers (TCE), comprised of a tumor targeting domain linked to CD3 binding domain, function by bridging target-positive tumors and CD3-expressing effector cells enabling redirected cell-mediated killing cells. Although the majority molecules in clinical development incorporate tumor-targeting antibody-based domains, many tumor-associated antigens derive from intracellular proteins are not accessible via antibody. Intracellular processed into...
<p>A prostate tumor cell line (PC3M-A2/beta 2M) was inoculated subcutaneously in the right flank of CD34-humanized NSG mice. Mice were treated intravenously at indicated time points with either vehicle or an ABBV-184 precursor molecule, and size monitored. Tumors experienced transient regression growth inhibition prior to harvest for analysis tumor-infiltrating immune cells.</p>
<p>A prostate tumor cell line (PC3M-A2/beta 2M) was inoculated subcutaneously in the right flank of CD34-humanized NSG mice. Mice were treated intravenously at indicated time points with either vehicle or an ABBV-184 precursor molecule, and size monitored. Tumors experienced transient regression growth inhibition prior to harvest for analysis tumor-infiltrating immune cells.</p>
<div>Abstract<p>CD3 bispecific T-cell engagers (TCE), comprised of a tumor-targeting domain linked to CD3 binding domain, function by bridging target-positive tumors and CD3-expressing effector T cells enabling redirected cell–mediated killing tumor cells. Although the majority molecules in clinical development incorporate antibody-based domains, many tumor-associated antigens derive from intracellular proteins are not accessible targeting via antibody. Intracellular processed...
<div>Abstract<p>The antiapoptotic protein BCL2 plays critical roles in regulating lymphocyte development and immune responses, has also been implicated tumorigenesis tumor survival. However, it is unknown whether for antitumor responses. We evaluated venetoclax, a selective small-molecule inhibitor of BCL2, would influence the activity checkpoint inhibitors (ICI). demonstrate mouse syngeneic models that venetoclax can augment efficacy ICIs accompanied by increase PD-1+ T effector...